Caribou Biosciences (CRBU) ends its CAR-T programs: the cash left for a strategic review

Caribou Biosciences (Nasdaq: CRBU) said after the close on Tuesday, October 6, 2026 that it will stop developing its two allogeneic CAR-T cell therapies, vispa-cel and CB-011, make a substantial cut to its workforce and evaluate strategic alternatives, including a merger or acquisition. The headline reached our news feed at 4:34 p.m. ET. In after-hours trading CRBU was 12.4% lower one minute later and 15.01% lower after ten minutes, falling from $0.80 to $0.68. Fourteen minutes after the headline it traded at $0.675, 15.62% below the pre-headline level.

The company said the financing environment for allogeneic CAR-T therapies had made it increasingly difficult to secure the capital needed to advance the two programs. Wedbush Securities is its exclusive financial adviser for the review. Vispa-cel, formerly CB-010, is an off-the-shelf anti-CD19 therapy for relapsed or refractory B cell non-Hodgkin lymphoma that Caribou describes as ready for a pivotal trial, with FDA alignment on the phase 3 design already reached. CB-011 is an anti-BCMA therapy for relapsed or refractory multiple myeloma. Their phase 1 trials, ANTLER and CaMMouflage, are being wound down.

Caribou Biosciences strategic alternatives: cash against market value

A biotech with no programs in development is valued mainly on its balance sheet. The table sets the last reported balance against the price paid for CRBU on Tuesday evening.

CRBU traded below its June 30 cash per share before the announcement, so at $0.80 the price already gave the pipeline no value on top of the June balance. The October 6 decision ended the chance that a phase 3-ready lymphoma asset would be funded inside Caribou, and it added an exit bill. The company's 8-K estimates $10 million to $11 million of severance, continued healthcare coverage and related costs, plus $5 million to $8 million to wind down the ANTLER and CaMMouflage trials.

The June 30 balance is also three months old. Caribou lost $24.3 million in the second quarter, and the third quarter's spending and the restructuring costs both come out of that cash before any transaction can close. The company did not give a headcount for the cut. Its annual report listed 97 full-time employees as of February 27, 2026, and most affected employees are scheduled to leave in the fourth quarter. At $0.68, CRBU traded below two-thirds of its June 30 cash per share.

How Caribou got here

In August, Caribou said its cash would fund its operating plan through the end of 2027, including CB-011 dose expansion and start-up work on ANTLER-3, the planned pivotal trial of vispa-cel, and that it was exploring ways to fund ANTLER-3 in full. Seven weeks later it stopped both programs.

1. July 6, 2023: Pfizer bought 4,690,431 Caribou shares at $5.33 each, a $25 million equity investment that Caribou used to advance CB-011.
2. April 24, 2025: Caribou narrowed its pipeline to CB-010 and CB-011, stopped its lupus and acute myeloid leukemia programs and its preclinical research, and cut 47 employees, about 32% of its workforce.
3. May 7, 2026: with first-quarter results, Caribou reported FDA alignment on the design of ANTLER-3, a randomized phase 3 trial of about 250 patients with second-line large B cell lymphoma.
4. August 13, 2026: second-quarter results showed $113.8 million of cash, cash equivalents and marketable securities, a net loss of $24.3 million and runway guidance through the end of 2027.
5. October 6, 2026: Caribou stopped vispa-cel and CB-011, announced a substantial workforce reduction and opened a strategic review with Wedbush Securities.

How strategic reviews at cash-rich biotechs usually end

A listed biotech with cash and no active programs usually ends in one of three ways. In a reverse merger, a private drug developer merges into it to gain the listing and the cash, and existing shareholders keep a minority of the combined company. In a cash acquisition, a buyer pays roughly the expected net cash, often with a contingent value right attached. In a wind-down, the board distributes what remains after liabilities.

The cash-acquisition route has a recent CAR-T precedent. Cargo Therapeutics stopped its lead CAR-T trial in January 2025, and in July 2025 it agreed to be acquired by Concentra Biosciences for $4.379 a share in cash plus a contingent value right. The right paid 100% of Cargo's closing net cash above $217.5 million and 80% of net proceeds from any disposal of its product candidates within two years. Concentra used the same structure for IGM Biosciences and Kronos Bio in 2025. In a deal built that way, the price per share tracks the cash left at closing, so each month of spending and each dollar of restructuring cost before signing comes out of what CRBU shareholders receive.

Beyond cash, the review has vispa-cel to offer: an agreed phase 3 design and 85 patients treated in the ANTLER trial as of a March 6, 2026 data cutoff.